Chat with us
Research Assistance
Online
  • Please enter your first name.

Canada Point-Of-Care Molecular Diagnostics Market Size & Outlook

The point-of-care molecular diagnostics market in Canada is expected to reach a projected revenue of US$ 618.4 million by 2033. A compound annual growth rate of 7.2% is expected of Canada point-of-care molecular diagnostics market from 2025 to 2033.

  • Clinical Diagnostics
    • Cancer Diagnostics
      • Point-of-Care Molecular Diagnostics Market Outlook
Revenue, 2024 (US$M)
$330.1
Forecast, 2033 (US$M)
$618.4
CAGR, 2025 - 2033
7.2%
Report Coverage
Canada
Canada Point-Of-Care Molecular Diagnostics Market, 2021-2033 (US$M)

This page contains premium content. Request sample data or start your free trial to explore Horizon.

  • ✔ Access to global market statistics
  • ✔ Access to company profiles
  • ✔ Free use-cases & research insights

No credit card required*

Global Market

Related Markets

Ask Prism AI anything about the point-of-care molecular diagnostics market

Get a cited answer from GVR research in seconds: segment shares, growth drivers, regulation and forecast assumptions.

Every answer starts with GVR research, and every figure is cited.Explore Prism AI

Canada point-of-care molecular diagnostics market highlights

  • The Canada point-of-care molecular diagnostics market generated a revenue of USD 330.1 million in 2024 and is expected to reach USD 618.4 million by 2033.
  • The Canada market is expected to grow at a CAGR of 7.2% from 2025 to 2033.
  • In terms of segment, infectious diseases was the largest revenue generating application in 2024.
  • Oncology is the most lucrative application segment registering the fastest growth during the forecast period.


Point-of-care molecular diagnostics market data book summary

Market revenue in 2024USD 330.1 million
Market revenue in 2033USD 618.4 million
Growth rate7.2% (CAGR from 2025 to 2033)
Largest segmentInfectious diseases
Fastest growing segmentOncology
Historical data2021 - 2023
Base year2024
Forecast period2025 - 2033
Quantitative unitsRevenue in USD million
Market segmentationOncology, Prenatal Testing, Endocrinology, Other Applications, Hematology, Infectious Diseases
Key market players worldwideRoche, Abbott Laboratories, Qiagen NV, Bayer AG, Nova Biomedical, Danaher Corp, Nipro Corp, Bio-Rad Laboratories Inc, Agilent Technologies Inc, BioMerieux SA, OraSure Technologies Inc, Abaxis


Other key industry trends

  • In terms of revenue, Canada accounted for 4.0% of the global point-of-care molecular diagnostics market in 2024.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2033.
  • In North America, U.S. point-of-care molecular diagnostics market is projected to lead the regional market in terms of revenue in 2033.
  • Mexico is the fastest growing regional market in North America and is projected to reach USD 410.6 million by 2033.

The development of POC tests for the detection of COVID-19 by key manufacturers in Canada is projected to drive the country’s market growth. In May 2020, Switch Health Holdings, Inc.—a Canada based health solutions provider, entered into a partnership agreement with Canadian laboratories for the expansion of COVID-19 testing across Canada.

The company introduced the first Mobile Rapid Testing Unit (MRTU), which allows POC-based COVID-19 testing. The Public Health Agency of Canada, National Molecular Microbiology Diagnostics User Group, and Canadian Public Health Association are actively involved in generating awareness about target diseases and providing pertinent diagnostic support.

No credit card required*

Publish Date: Aug 05, 2025

Customize the Report

20% free customization

Include
Countries, segments, points
Tailor
To your product definition
Extend
Deeper competitor detail
Or
A fully bespoke study
Turnaround
5–10 working days

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Point-Of-Care Molecular Diagnostics Market Companies

NameProfile# EmployeesHQWebsite
Abbott LaboratoriesView profile 114,000100 Abbott Park Road, Abbott Park, IL, United States, 60064-6400www.abbottinvestor.com
BioMerieux SAView profile 13,982Marcy l’Etoile, Lyon, France, 69280www.biomerieux.com
Danaher CorpView profile 63,0002200 Pennsylvania Avenue, N.W., Suite 800W, Washington, DC, United States, 20037-1701www.danaher.com
Agilent Technologies IncView profile 17,7005301 Stevens Creek Boulevard, Santa Clara, CA, United States, 95051www.agilent.com
Bio-Rad Laboratories IncView profile 8,0301000 Alfred Nobel Drive, Hercules, CA, United States, 94547www.bio-rad.com
Qiagen NVView profile 5,900Hulsterweg 82, Venlo, LI, Netherlands, 5912 PLwww.qiagen.com
Nova BiomedicalView profile 501-1000Waltham, Massachusetts, United States, North Americawww.novabio.us
Bayer AGView profile 99,723Kaiser-Wilhelm-Allee 1, Leverkusen, NW, Germany, 51368www.bayer.com
Nipro CorpView profile 39,7133-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510www.nipro.co.jp
RocheView profile 10001+Basel, Basel-Stadt, Switzerland, Europewww.roche.com

Canada Point-of-Care Molecular Diagnostics Market Outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Point-of-Care Molecular Diagnostics Market Outlook will help companies and investors design strategic landscapes.


Infectious Diseases was the largest segment with a revenue share of 50.35% in 2024.

Horizon Databook has segmented the Canada point-of-care molecular diagnostics market based on oncology, prenatal testing, endocrinology, other applications, hematology, infectious diseases covering the revenue growth of each sub-segment from 2021 to 2033.




The development of POC tests for the detection of COVID-19 by key manufacturers in Canada is projected to drive the country’s market growth. In May 2020, Switch Health Holdings, Inc.—a Canada based health solutions provider, entered into a partnership agreement with Canadian laboratories for the expansion of COVID-19 testing across Canada.

The company introduced the first Mobile Rapid Testing Unit (MRTU), which allows POC-based COVID-19 testing. The Public Health Agency of Canada, National Molecular Microbiology Diagnostics User Group, and Canadian Public Health Association are actively involved in generating awareness about target diseases and providing pertinent diagnostic support.

  • Canada Point-Of-Care Molecular Diagnostics Market Application Outlook (Revenue, USD Million , 2021-2033)
    • Oncology
    • Prenatal Testing
    • Endocrinology
    • Other Applications
    • Hematology
    • Infectious Diseases
  • Canada Point-Of-Care Molecular Diagnostics Market Technology Outlook (Revenue, USD Million , 2021-2033)
    • PCR-based
    • Genetic Sequencing based
    • Hybridization based
    • Microarray based
  • Canada Point-Of-Care Molecular Diagnostics Market Test Location Outlook (Revenue, USD Million , 2021-2033)
    • OTC
    • POC
  • Canada Point-Of-Care Molecular Diagnostics Market End-use Outlook (Revenue, USD Million , 2021-2033)
    • Decentralised Labs
    • Hospitals
    • Home care
    • Assisted Living Healthcare Facilities
    • Others

Reasons to subscribe to Point-of-Care Molecular Diagnostics Market Outlook databook

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Point-of-Care Molecular Diagnostics Market Outlook databook

  • Our clientele includes a mix of Point-of-Care Molecular Diagnostics Market Outlook companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Canada Point-of-Care Molecular Diagnostics Market Outlook, including forecasts for subscribers. This country databook contains high-level insights into Canada Point-of-Care Molecular Diagnostics Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.

Canada Point-Of-Care Molecular Diagnostics Market, 2021-2033 (US$M)

No Access Stack Chart

Canada Application - Point-of-care Molecular Diagnostics Market Statistics, 2024 - 2033 (US$M)

No Access Pie Chart

Canada Application - Point-of-care Molecular Diagnostics Market Statistics, 2024 - 2033 (USD Million)

No Access

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more